Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eran Zimran has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Adir Shaulov

    Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel

    14 shared publications
  • Eyal Lebel

    Department of Hematology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel

    14 shared publications
  • Moshe E. Gatt

    Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel

    14 shared publications
  • Batia Avni

    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel

    13 shared publications
  • Nathalie Asherie

    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    13 shared publications
  • Polina Stepensky

    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel

    13 shared publications

Latest Publications

  • DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia

    by Arnon Haran, Avital Wasserstrom, Vladimir Vainstein, Romi Kazoom, Ela Shai, Ariela Arad, Batia Roth, Noa Buchman, Yosef Kalish, Eran Zimran

    Introduction: Thrombosis and bleeding events are major causes of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). The contribution of non‐driver mutations, in particular mutations in DNMT3A , TET2, and ASXL1 (collectively DTA) to thrombo‐hemorrhagic risk remains unclear. Methods: We conducted a retrospective analysis of 180 patients with MPN undergoing next generation sequencing to evaluate the association between DTA mutations and major bleeding and thrombotic events occurring from 3 years prior to diagnosis through follow‐up. Patients were stratified by disease subtype, and Cox proportional hazards models were used for univariate and multivariate analyses. Results: DTA mutations were present in 40% of the patients. 52 (29%) patients suffered from arterial or venous thrombotic events either following diagnosis or as early as 3 years prior to diagnosis, and 20 (11%) experienced major bleeding events during the same period. In patients with PV and ET, DNMT3A and TET2 (DT) mutations were significantly associated with venous thrombosis (HR 5.6, 95% CI 1.6–19.1) and were also associated with major bleeding in univariate analyses (HR 6.7, 95% CI 1.7–26.9). The association with venous thrombosis remained significant after multivariable adjustment, whereas the association with major bleeding was attenuated after adjustment for age and smoking status (HR 4.1, 95% CI 0.9–19.2). No such associations were observed in patients with myelofibrosis. Conclusion: Our findings highlight an association between DT mutations and thrombotic and bleeding complications in patients with PV and ET and support further evaluation of molecular markers as contributors to thrombo‐hemorrhagic risk in MPN.

  • Open Access

    Targeting the 3’ splice site by a decoy oligonucleotide attenuates U2AF1 splicing activity and inhibits leukemia

    by Carla Azar-Koussa, Marina Sakran, Efraim Rahamim, Anurag V Prabhu, Samar Salem, Adina Heinberg, Zahava Siegfried, Meital Ben-David-Naim, Eran Zimran, Erez Levanon, et al.

    Recurrent mutations in spliceosomal genes are a hallmark of myeloid malignancies, with SF3B1 , SRSF2 , U2AF1 and ZRSR2 among the most frequently affected. These alterations are typically heterozygous, mutually exclusive missense mutations targeting highly conserved residues, reflecting a selective pressure to maintain a dysregulated yet essential splicing machinery. This constraint suggests that leukemic cells remain dependent on residual splicing activity, exposing a potential therapeutic vulnerability that extends beyond genetically defined subsets. For example, a previously developed therapeutic, Pladienolide B, is a potent cancer cell growth inhibitor targeting the SF3B1 subunit of the spliceosome 1,2 . Here we present an RNA decoy-based strategy to disrupt 3′ splice site recognition by competitively engaging components of the spliceosomal machinery. We engineered a chemically stabilized RNA decoy that mimics the 3’ splice site (3′SS decoy), thereby sequestering proteins involved in 3’ splice site recognition from endogenous pre-mRNA targets. Although the decoy is expected to engage multiple components of the 3′ splice site recognition complex, U2AF1 was used as the primary molecular readout to assess target engagement and downstream effects. To enable intracellular delivery, decoys were encapsulated in lipid nanoparticles (LNPs), facilitating efficient uptake in leukemic systems. We show that LNP-encapsulated decoys are efficiently delivered into leukemic cells, including established cell lines and patient-derived blasts, and directly engage components of the splicing machinery. Decoy treatment induces widespread alterations in RNA splicing programs and impairs leukemic cell fitness in vitro. Importantly, systemic administration of the 3’SS decoy significantly reduces leukemia burden in an in vivo xenograft model. Notably, these effects are observed independently of spliceosomal mutational status, supporting a broader dependency of leukemic cells on intact splicing factor function. Together, our findings establish decoy-mediated disruption of splicing factor activity as a mechanistically targeted therapeutic strategy and identify LNPs as an effective platform for the delivery of RNA-based modulators of essential RNA-protein interactions in myeloid malignancies.

  • Open Access

    Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

    by Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Eran Zimran, Miri Assayag, Tatyana Dubnikov Sharon, Marjorie Pick, Eyal Lebel, Adir Shaulov, et al.

  • Open Access

    Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

    by Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Eran Zimran, Miri Assayag, Tatyana Dubnikov Sharon, Marjorie Pick, Eyal Lebel, Adir Shaulov, et al.

  • Open Access

    Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

    by Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Eran Zimran, Miri Assayag, Tatyana Dubnikov Sharon, Marjorie Pick, Eyal Lebel, Adir Shaulov, et al.

  • Open Access

    High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)

    by Ariela Arad, Maya Katz, Eyal Lebel, Yosef Kalish, Miri Assayag, Batia Avni, Shlomo Elias, Sigal Grisariu, Ela Shai, Shlomit Kfir-Erenfeld, et al.

    Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated substantial efficacy in relapsed and/or refractory multiple myeloma. While toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been well characterized, the incidence and clinical consequences of the coagulopathy associated with CRS remain underexplored. Methods: We conducted a prospective analysis of 108 adult patients with multiple myeloma or light chain amyloidosis treated with the academic anti-BCMA CAR-T HBI0101 in a single-center trial (NCT04720313). Coagulopathy was evaluated via serial fibrinogen measurements, with hypofibrinogenemia defined as p < 0.001), number of tocilizumab doses (p < 0.001), peak levels of the inflammation markers LDH (p = 0.001) and ferritin (p = 0.006), and neutropenia (p = 0.33). Five thrombotic events (4.6%) and three minor bleeding events (2.7%) occurred within 3 months post-CAR-T infusion and were not associated with degree of coagulopathy or CRS. No cases of major bleeding or fatal thrombosis occurred. Conclusions: CRS-related coagulopathy is common following BCMA-targeted CAR-T treatment and correlates closely with CRS severity. Despite the high rate of laboratory coagulopathy, thrombosis and bleeding events were infrequent, suggesting the benefit of the prophylactic strategies used.


  • Open Access

    Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms

    by Ayala Gat, Romi Kazoom, Inbal Shapira, Ela Shai, Batia Roth Jelinek, Noa Buchman, Yosef Kalish, Ariela Arad, Eran Zimran

    Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of novel risk factors to better predict these complications. We performed laboratory coagulation testing and driver mutation profiling from peripheral blood of patients with MPN. Patients’ history of comorbidities, hematological variables and thrombosis and/or bleeding events were collected retrospectively at the time of testing. Patients were then followed for a median of 3.3 years for incident events. 198 patients were included in the study. Thrombotic events occurred in 41% of the patients. Age, cardiovascular comorbidities and constitutional symptoms were significantly associated with thrombosis, as well as elevated von Willebrand Factor (vWF): Antigen, vWF: Activity and factor VIII levels. Elevated vWF: Antigen levels remained independent in multivariate analysis and were predictive of incident thrombosis. Bleeding events occurred in 26% of the patients. vWF: Activity ≤ 30%, vWF: Activity-to-antigen ratio of ≤ 0.7, a platelet count of ≥ 500*10 9 /L and JAK2 V617F variant allele frequency (VAF) of ≥ 50% were predictive of total (including minor) bleeding events. However, only JAK2 V617F VAF of ≥ 50% was predictive of major and clinically relevant non-major bleeding. Extreme thrombocytosis defined by a platelet count of ≥ 1000*10 9 /L was not associated with bleeding or acquired vWF syndrome. vWF profiling and JAK2 V617F VAF contribute to thrombosis and bleeding risk assessment in patients with MPNs and should be incorporated routinely at diagnosis and during follow-up.


  • DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms

    by Arnon Haran, Avital Wasserstrom, Shlomzion Aumann, Vladimir Vainstein, Romi Kazoom, Batia Roth Jelinek, Ariela Arad, Noa Buchman, Ela Shai, Yossi Kalish, et al.

    Background: Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocytosis (ET), and primary or secondary myelofibrosis (MF), have a remarkably increased risk of thrombotic events (TEs). Scores to assess the risk of thrombosis are limited, while some patients paradoxically suffer from bleeding complications that are even less predictable. Next-generation sequencing (NGS) enables detection of somatic mutations in myeloid-related genes, in addition to the common driver mutations in JAK2, CALR, and MPL. Mutations in DNMT3A, TET2 and ASXL1 (collectively, DTA) are associated with an increased risk of arterial TEs in individuals with clonal hematopoiesis [Jaiswal, NEJM 2017]. Several recent studies addressed the relationship between DTA mutations and thrombohemorrhagic complications in MPN, however, results have been inconsistent and mostly focused on PV. Methods: We evaluated the association between NGS mutational panel data and thrombohemorrhagic complications in patients with MPN admitted for evaluation in our institution between 2020-2023. NGS was performed on DNA extracted from bone marrow samples, using the Archer VariantPlex Myeloid panel. Clinical and demographic data were collected retrospectively from electronic medical records. The study was approved by the local IRB [HMO-0533-19]. Results:154 patients were included in the study. Median age was 65 years and 52% were female. 50% had a diagnosis of PV, 33% essential thrombocytosis ET, and 17% primary or secondary MF. 75% of the patients harbored a JAK2 V617F mutation, 14% and 3% harbored CALR and MPL mutations, respectively, and 8% were negative for all three MPN driver mutations. In NGS analyses, over 60% of the patients harbored at least one additional mutation; 45% harbored one or more DTA mutations. 67% of the patients had at least one cardiovascular risk factor, 73% had high-risk disease defined by age>60 years or history of thrombosis, and over 70% received at least one line of cytoreductive therapy. Of 154 patients, 35% had a history of TEs (20% arterial, 15% venous) and 25% had experienced major or minor bleeding events. The high prevalence of bleeding manifestations in our study population may suggest an underestimation of the bleeding burden in MPN. In the entire patient population, the presence of hypertension (OR 3.5, 95% CI 1.6-7.9, p = 0.002), diabetes mellitus (OR 3.3, 95% CI 1.2-8.2, p = 0.01), and JAK2 V617F (OR 2.4, 95% CI 1.1-5.6, p = 0.04) were significantly associated with the occurrence of TEs, while DTA mutations were not. However, in the PV subgroup, DTA as well as TET2 mutations specifically were significantly associated with venous TEs (OR 3.750, 95% CI 1.0-11.8, p = 0.04). Age was not found to be associated with the occurrence of TEs in this cohort, perhaps owing to a large proportion of high-risk disease in younger patients. Hypertension was also a significant predictor of major bleeding events (OR 4.5, 95% CI 1.2-15.8, p = 0.02). We observed a significant association between DTA mutations and major bleeding (OR 2.8, 95% CI 1.04-7.9, p = 0.04), previously reported only in patients with ET and DNMT3A mutations [Furuya, BJH, 2024]. A significant association was also observed between JAK2 V617F allelic burden and total bleeding events (OR 1.17 for each 10% increase, p = 0.003), not previously reported in MPN. In multivariate analysis, DTA mutations retained significance as a predictor of hemorrhagic complications. Conclusions: DTA mutations detected with a clinically used NGS panel in patients with MPN are associated with increased risk of bleeding complications, as well as increased thrombotic risk in a subgroup of patients. These findings support the incorporation of molecular panel analyses in thrombosis and bleeding risk assessment in MPN, and merit further investigation.


  • Open Access

    The Utility of a Coagulation Laboratory Profile in Addition to Clinical Risk Factors for Thrombosis Risk Evaluation in Patients with Myeloproliferative Neoplasms: A Pilot Study

    by Inbal Shapira, Ela Shai, Yossef Kalish, Uria Tsubary, Shlomzion Aumann, Ariela Arad, Batia Roth Jelinek, Noa Buchman, Moshe E Gatt, Eran Zimran

    Background: Patients (pts) with myeloproliferative neoplasms (MPN) have a significantly increased risk of arterial and venous thrombotic events (TEs), while some pts may paradoxically suffer from bleeding manifestations. Thrombosis risk evaluation in polycythemia vera (PV) and essential thrombocythemia (ET) has important implications for patient management, however, the currently used risk stratification models are extremely limited. Methods: We designed a pilot study to assess the utility of an expanded coagulation laboratory profile in addition to other clinical variables for thrombosis and bleeding risk evaluation in a heterogenous MPN patient population. Our laboratory profile included PT, aPTT, fibrinogen, D-dimer, von-Willebrand Factor (vWF) antigen and activity testing, platelet (PLT) aggregation studies and thrombin generation assay (TGA, ST-Genesia, Stago, France), along with CBC and comprehensive biochemistry studies. Blood was drawn from pts visiting the hematology clinics or day care at Hadassah Medical Center. Clinical and demographic data were collected retrospectively from electronic medical records. The study was approved by the local IRB committee. Results:74 pts were included in the study; the mean age was 59.7 years and 51% were women. Sixty percent had a diagnosis of PV, 20% had ET, 17.6% had myelofibrosis (MF) and 2.7% had MPN unclassifiable. 78% of the pts harbored a JAK2V617F mutation, 8% and 2.7% harbored CALR and MPL mutations, respectively, and 11% were negative to all three MPN driver mutations. 63% of the pts had at least one cardiovascular risk factor, most commonly hypertension (HTN) and dyslipidemia. Most of the pts were treated with antiplatelet agents (62%), anticoagulants (16%) and/or cytoreductive agents (58%). Of 74 pts, 31% had a history of TEs (20% arterial, 11% venous), 22% reported suffering from microvascular symptoms, and 20% had experienced bleeding. The high rate of bleeding manifestations in our study population suggests an underestimation of the bleeding burden in MPN, as proposed by our group previously [Rottenstreich, Eur J Intern Med 2017]. Other patient characteristics were overall comparable to MPN patient populations in other studies (Table 1). In multivariate analyses, history of TEs was significantly associated with older age, type 2 diabetes mellitus (DM2), HTN and dyslipidemia, but not with gender, MPN subtype, driver mutation status or smoking. Pts with history of TEs had significantly lower hematocrit and prolonged PT/INR, associated with a higher rate of treatment with cytoreduction and anticoagulation, respectively, in these pts. Interestingly, pts with TEs had significantly higher vWF antigen levels (p=0.007), which were independent of age, blood counts and treatments, a finding not previously reported in MPN. No association was observed between TEs and PLT or WBC counts, D-dimer levels and vWF activity (Table 2), however, vWF activity was decreased in pts with higher PLT counts. TGA was of key interest in this study. In 62 pts not receiving anticoagulation, we observed an association between prolonged lag time (suggesting decreased coagulability) and older age, male gender and (near significant trend) JAK2V617 negative status, but did not find a correlation to TEs, blood counts and other variables. PLT aggregation indices were not associated with TEs, bleeding history or blood counts. In multivariate logistic regression analyses, history of DM2 and HTN, and vWF antigen levels, showed the strongest association to TEs, which was independent of age, blood counts and all other variables. A risk-model incorporating these variables showed a sensitivity of 77% and specificity of 92% for history of TEs in our study population. Conclusions: Despite being limited by a small and heterogenous study population and retrospective data collection; these findings support the utility of a coagulation laboratory profile in the evaluation of thrombosis and bleeding risk in MPN. The potential of TGA in risk evaluation in MPN is intriguing but merits further research. The multivariate risk-model incorporating history of DM2 and HTN along with vWF antigen levels merits validation in larger studies. Based on this pilot, a prospective study following over 250 pts with PV and ET (excluding overt MF) was initiated. This study will include NGS mutational profiling and JAK2V617F allele burden testing and omit the use of PLT aggregation studies.

  • Open Access

    Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation

    by Yarden Irit Cohen, Eyal Lebel, Eran Zimran, Adir Shaulov, Polina Stepensky, Sigal Grisariu, Batia Avni